| scholarly article | Q13442814 |
| P50 | author | John Anthony Hardy | Q6237755 |
| P2093 | author name string | Henry Houlden | |
| Eleanna Kara | |||
| P2860 | cites work | alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis. | Q67208294 |
| Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synuclein-positive inclusions | Q80485457 | ||
| PINK1 and Parkin Flag Miro to Direct Mitochondrial Traffic | Q82480761 | ||
| R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family | Q82990460 | ||
| PINK1/Parkin direct mitochondria to autophagy | Q83120705 | ||
| Mitochondrial diseases | Q83827338 | ||
| Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease | Q84214782 | ||
| PINK1 points Parkin to mitochondria | Q84259115 | ||
| Neuroaxonal Dystrophy in Calcium-Independent Phospholipase A2β Deficiency Results from Insufficient Remodeling and Degeneration of Mitochondrial and Presynaptic Membranes | Q84670136 | ||
| The age at motor symptoms onset in LRRK2-associated Parkinson's disease is affected by a variation in the MAPT locus: a possible interaction | Q84903914 | ||
| TFEB regulates lysosomal proteostasis | Q86082443 | ||
| Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria | Q21563375 | ||
| Tubulin Seeds α-Synuclein Fibril Formation | Q24291881 | ||
| Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP | Q24293723 | ||
| PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility | Q24296955 | ||
| PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 | Q24297155 | ||
| The PINK1/Parkin-mediated mitophagy is compromised by PD-associated mutations | Q24297798 | ||
| Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism | Q24301367 | ||
| Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies | Q24307627 | ||
| RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk | Q24315688 | ||
| Parkin is recruited selectively to impaired mitochondria and promotes their autophagy | Q24317471 | ||
| The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in mitochondrial trafficking | Q24319150 | ||
| De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood | Q24320029 | ||
| Autophagosomes form at ER-mitochondria contact sites | Q24322618 | ||
| Interplay of LRRK2 with chaperone-mediated autophagy | Q24322747 | ||
| A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease | Q24633417 | ||
| α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells | Q24633663 | ||
| Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. | Q24634577 | ||
| Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein | Q24655848 | ||
| TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT | Q26851112 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| α-Synuclein in Lewy bodies | Q27860680 | ||
| Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity | Q27934988 | ||
| Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase | Q28116395 | ||
| Loss of β-Glucocerebrosidase Activity Does Not Affect Alpha-Synuclein Levels or Lysosomal Function in Neuronal Cells | Q28118642 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Mitochondria get a Parkin' ticket | Q57269925 | ||
| Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy | Q57306350 | ||
| Identification of VPS35 mutations replicated in French families with Parkinson disease | Q59697029 | ||
| An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. | Q64768245 | ||
| Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue | Q36539066 | ||
| Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations | Q36559669 | ||
| Pathogenic mutation in VPS35 impairs its protection against MPP(+) cytotoxicity | Q36609844 | ||
| Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease | Q36622356 | ||
| New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. | Q36659362 | ||
| Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays | Q36719174 | ||
| Screening for VPS35 mutations in Parkinson's disease | Q36775809 | ||
| Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits | Q36787223 | ||
| Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy. | Q36839019 | ||
| A novel α-synuclein missense mutation in Parkinson disease | Q36841475 | ||
| CSF1R mutations link POLD and HDLS as a single disease entity | Q36841490 | ||
| Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease | Q36841500 | ||
| The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features | Q36852789 | ||
| Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations | Q36854793 | ||
| Lewy Body-like α-Synuclein Aggregates Resist Degradation and Impair Macroautophagy | Q36873680 | ||
| α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? | Q36925651 | ||
| Pantothenate kinase-associated neurodegeneration is not a synucleinopathy | Q37016212 | ||
| Lysosomes in iron metabolism, ageing and apoptosis | Q37079830 | ||
| Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. | Q37102231 | ||
| Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease | Q37105393 | ||
| Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family | Q37110628 | ||
| Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. | Q37209217 | ||
| Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking | Q37219276 | ||
| AF-6 is a positive modulator of the PINK1/parkin pathway and is deficient in Parkinson's disease. | Q37243137 | ||
| Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. | Q37330540 | ||
| A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies | Q37346468 | ||
| Adult onset leukodystrophy with neuroaxonal spheroids: clinical, neuroimaging and neuropathologic observations | Q37375281 | ||
| Lysosomal impairment in Parkinson's disease | Q37461364 | ||
| Mitophagy and Parkinson's disease: the PINK1-parkin link. | Q37587126 | ||
| Pallidopyramidal disease: a misnomer? | Q37772452 | ||
| Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations | Q37776461 | ||
| Rare causes of dystonia parkinsonism | Q37778764 | ||
| The Parkinson disease protein α-synuclein inhibits autophagy | Q37820817 | ||
| Hereditary diffuse leukoencephalopathy with spheroids: clinical, pathologic and genetic studies of a new kindred | Q48624902 | ||
| Prion-like acceleration of a synucleinopathy in a transgenic mouse model | Q48965892 | ||
| Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations | Q48974297 | ||
| Pallido-pyramidal disease. | Q51345009 | ||
| Involvement of spinal motor neurons in parkin-positive autosomal recessive juvenile parkinsonism | Q51727066 | ||
| Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration | Q51896097 | ||
| Progressive atrophy of the globus pallidus (primary atrophy of the pallidal system). A system disease of the paralysis agitans type, characterized by atrophy of the motor cells of the corpus striatum. A contribution to the function of the corpus str | Q52097854 | ||
| Axonal dystrophy in the gracile nucleus in children and young adults. Reappraisal of the incidence and associated diseases. | Q54198367 | ||
| Dangerous duet: LRRK2 and α-synuclein jam at CMA | Q54441670 | ||
| ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. | Q54532651 | ||
| A truncating mutation in ATP13A2 is responsible for adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers. | Q54608818 | ||
| THE METABOLISM OF GLUCOCEREBROSIDES. I. PURIFICATION AND PROPERTIES OF A GLUCOCEREBROSIDE-CLEAVING ENZYME FROM SPLEEN TISSUE | Q55037613 | ||
| Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. | Q55042329 | ||
| An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria | Q28205616 | ||
| A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome | Q28210032 | ||
| A block of autophagy in lysosomal storage disorders | Q28252016 | ||
| The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration | Q28252508 | ||
| Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration | Q28263454 | ||
| Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease | Q28275257 | ||
| The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease | Q28287883 | ||
| Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function | Q28289653 | ||
| Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13 | Q28298493 | ||
| FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome | Q28302099 | ||
| Genetics of Neurodegeneration with Brain Iron Accumulation | Q28304487 | ||
| Pantothenate kinase-associated neurodegeneration: altered mitochondria membrane potential and defective respiration in Pank2 knock-out mouse model | Q28505781 | ||
| Development and Characterization of a New Parkinson's Disease Model Resulting from Impaired Autophagy | Q28511536 | ||
| Compartmentalization of mammalian pantothenate kinases | Q28593602 | ||
| Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy | Q29614178 | ||
| Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization | Q29615622 | ||
| Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation | Q29615640 | ||
| The PINK1/Parkin pathway regulates mitochondrial morphology | Q29615641 | ||
| Autophagy in human health and disease | Q29620121 | ||
| PINK1-dependent recruitment of Parkin to mitochondria in mitophagy | Q29620567 | ||
| Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice | Q29620597 | ||
| α-Synuclein mutations cluster around a putative protein loop | Q30430404 | ||
| Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic | Q30525658 | ||
| Parkin disease: a clinicopathologic entity? | Q30594306 | ||
| Neurodegeneration with brain iron accumulation | Q31029813 | ||
| Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species | Q33360061 | ||
| Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy | Q33444800 | ||
| Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders | Q33677320 | ||
| Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms | Q33697904 | ||
| Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). | Q33867989 | ||
| A one base pair deletion in the canine ATP13A2 gene causes exon skipping and late-onset neuronal ceroid lipofuscinosis in the Tibetan terrier | Q34055332 | ||
| Two phosphatidylinositol 4-kinases control lysosomal delivery of the Gaucher disease enzyme, β-glucocerebrosidase. | Q34254743 | ||
| Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines | Q34257471 | ||
| Direct observation of the interconversion of normal and toxic forms of α-synuclein | Q34277399 | ||
| Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. | Q34313397 | ||
| Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. | Q34330786 | ||
| A Tangled Web – Tau and Sporadic Parkinson's Disease | Q37855547 | ||
| Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond | Q37880734 | ||
| Neuropathology underlying clinical variability in patients with synucleinopathies | Q37896515 | ||
| Pathological roles of α-synuclein in neurological disorders | Q37947720 | ||
| Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations | Q37949887 | ||
| α-Synuclein in Parkinson's disease | Q37987146 | ||
| The neuropathology of genetic Parkinson's disease | Q37997386 | ||
| The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders | Q38012653 | ||
| αSynuclein and Mitochondrial Dysfunction: A Pathogenic Partnership in Parkinson’s Disease? | Q38022031 | ||
| Lysosome-dependent pathways as a unifying theme in Parkinson's disease. | Q38038561 | ||
| Exosomes-associated neurodegeneration and progression of Parkinson's disease | Q38079242 | ||
| The VPS35 gene and Parkinson's disease | Q38093808 | ||
| Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study | Q39030130 | ||
| Alpha‐synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson’s disease | Q39358210 | ||
| α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. | Q39372978 | ||
| Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. | Q39595928 | ||
| Molecular interaction of α-synuclein with tubulin influences on the polymerization of microtubule in vitro and structure of microtubule in cells | Q39787734 | ||
| Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity | Q39914071 | ||
| The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease | Q40669171 | ||
| Mitochondria drive autophagy pathology via microtubule disassembly: a new hypothesis for Parkinson disease | Q41842350 | ||
| Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses. | Q41859552 | ||
| Relationship of neighboring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease | Q42002660 | ||
| Mutant A53T α-Synuclein Induces Neuronal Death by Increasing Mitochondrial Autophagy | Q42089641 | ||
| Hereditary diffuse leukoencephalopathy with spheroids: ultrastructural and immunoelectron microscopic studies | Q42130117 | ||
| Neuroferritinopathy: a window on the role of iron in neurodegeneration. | Q42436187 | ||
| Eye of the tiger-like MRI in parkinsonian variant of multiple system atrophy | Q42455961 | ||
| Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation | Q42512292 | ||
| Lewy body pathology in a patient with a homozygous parkin deletion | Q42520606 | ||
| Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. | Q42790455 | ||
| ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation | Q43121326 | ||
| PINK1 and Parkin complementarily protect dopaminergic neurons in vertebrates | Q44309628 | ||
| Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? | Q44479792 | ||
| Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene | Q44601366 | ||
| Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers | Q45039594 | ||
| Iron accumulation in syndromes of neurodegeneration with brain iron accumulation 1 and 2: causative or consequential? | Q46160795 | ||
| Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore | Q46241226 | ||
| Parallel PARKing: Parkinson’s Genes Function in Common Pathway | Q46840594 | ||
| Neuropathology provides clues to the pathophysiology of Gaucher disease | Q47247270 | ||
| First video report of static encephalopathy of childhood with neurodegeneration in adulthood | Q48172818 | ||
| PINK1-linked parkinsonism is associated with Lewy body pathology | Q48252842 | ||
| 100 years of Lewy pathology | Q48278741 | ||
| PLA2G6 mutations and Parkinson's disease | Q48291991 | ||
| Neurodegeneration in Parkinson disease: moving Lewy bodies out of focus | Q48295348 | ||
| Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation | Q48349192 | ||
| MRI, MR spectroscopy, and diffusion tensor imaging findings in patient with static encephalopathy of childhood with neurodegeneration in adulthood (SENDA) | Q48409469 | ||
| The spread of neurodegenerative disease | Q48488957 | ||
| Autosomal dominant adult neuronal ceroid lipofuscinosis: parkinsonism due to both striatal and nigral dysfunction | Q48552779 | ||
| Relationship between mitochondria and α-synuclein: a study of single substantia nigra neurons | Q48618580 | ||
| G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome | Q34335126 | ||
| Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein | Q34345614 | ||
| Genetic analysis of inherited leukodystrophies: genotype-phenotype correlations in the CSF1R gene | Q34376041 | ||
| The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease | Q34398442 | ||
| Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study | Q34408564 | ||
| Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome | Q34530192 | ||
| PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron | Q34568479 | ||
| Characterization of PLA2G6 as a locus for dystonia-parkinsonism | Q34593410 | ||
| ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease | Q34626200 | ||
| Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity | Q34636872 | ||
| PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria | Q34641661 | ||
| Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome | Q34726815 | ||
| Gaucher disease and the synucleinopathies | Q34795306 | ||
| Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration | Q35018106 | ||
| VPS35 mutations in Parkinson disease | Q35103751 | ||
| α-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher Diseases | Q35150090 | ||
| Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation | Q35286584 | ||
| Neuroferritinopathy in a French family with late onset dominant dystonia | Q35442453 | ||
| Parkinsonism among Gaucher disease carriers | Q35444509 | ||
| Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids | Q35705431 | ||
| Transmission of Synucleinopathies in the Enteric Nervous System of A53T Alpha-Synuclein Transgenic Mice | Q35707907 | ||
| Prion-like spread of protein aggregates in neurodegeneration | Q35946138 | ||
| Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice | Q35946149 | ||
| The Use of Next-Generation Sequencing in Movement Disorders | Q35955394 | ||
| Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders | Q35960413 | ||
| Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis | Q35997567 | ||
| Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. | Q36066469 | ||
| Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases | Q36083108 | ||
| A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants | Q36370223 | ||
| Parkin and mitofusins reciprocally regulate mitophagy and mitochondrial spheroid formation | Q36452057 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blepharospasm | Q883863 |
| parkinsonian syndrome | Q1531991 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 381-394 | |
| P577 | publication date | 2013-08-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Current Opinion in Neurology | Q15716647 |
| P1476 | title | The pallidopyramidal syndromes: nosology, aetiology and pathogenesis | |
| P478 | volume | 26 |
| Q36093991 | A diagnostic approach for neurodegeneration with brain iron accumulation: clinical features, genetics and brain imaging. |
| Q36382728 | Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease |
| Q55507401 | Expanding the Spectrum of Dopa-Responsive Dystonia (DRD) and Proposal for New Definition: DRD, DRD-plus, and DRD Look-alike. |
| Q37081945 | Genetic and phenotypic characterization of complex hereditary spastic paraplegia |
| Q88779837 | Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for? |
| Q47309944 | Multiple system atrophy: genetic risks and alpha-synuclein mutations. |
| Q87030479 | Neurodegeneration with Brain Iron Accumulation |
Search more.